BioinfometricsBioinfometrics logo mark — DNA double helix encoded as a financial candlestick chart on an upward trend axis. The dual-read mark simultaneously represents molecular biology and market data intelligence.

Bioinfometrics

Five Weeks of RASONQUE Sales Came to 89% of Lumakras’s Best US Year

Revolution Medicines booked $197.6 million of RASONQUE (daraxonrasib) sales in about five weeks after its August 26 approval in pancreatic cancer. Amgen’s SEC filings show Lumakras, the first KRAS drug, never topped $222 million a year in the US.

Illustration of five sample tubes of similar height under a dashed line, beside one much taller tube with an amber capsule above it and a short time bar beneath it
Martin DAVILABy Martin DAVILA11/12/20265

On November 4, Revolution Medicines reported its first quarter as a commercial company. RASONQUE (daraxonrasib), approved by the FDA on August 26 for adults with metastatic pancreatic cancer after at least one prior therapy, or who cannot take multi-drug chemotherapy, brought in $197.6 million of net product revenue. That covered about five weeks of sales.

RAS drugs have launched before. Amgen's Lumakras (sotorasib), approved in May 2021 for lung cancer with the KRAS G12C mutation, was the first. Its sales in Amgen's filings are the clearest yardstick for what RevMed just did.

How does the launch compare with the first KRAS drug?

Five weeks of RASONQUE sales equal 89% of the best full year Lumakras has had in the US.

US net product sales, $ millions. Grey bars: Lumakras by calendar year (2021 from its May approval). Green bar: RASONQUE in the quarter ended September 30, 2026, about five weeks on the market.

Source: Amgen Forms 10-K for 2021 to 2025; Revolution Medicines Form 8-K, November 4, 2026. US sales only, because RASONQUE is not yet sold outside the US. Lumakras also earned $63 million to $152 million a year outside the US from 2022 to 2025. RASONQUE launch revenue includes patients moving from an expanded access programme and initial stocking of wholesaler inventory.

View data
periodsales
202182
2022222
2023197
2024214
2025211
RASONQUE197.6

Lumakras's best US year was 2022, at $222 million. RASONQUE reached $197.6 million in roughly five weeks. That is 89% of that peak year, 2.4 times Lumakras's partial first year and 21% of everything Lumakras sold in the US from 2021 to 2025 combined ($926 million).

The same quarter makes the gap concrete. Amgen's latest 10-Q reports Lumakras US sales of $55 million for July to September 2026. RASONQUE sold 3.6 times as much in that quarter, while on the market for about five of its thirteen weeks.

Why is this launch so different?

The patient pool is one reason. KRAS G12C, the only mutation Lumakras targets, is a minority of lung cancers. Daraxonrasib is a multi-selective inhibitor of the active form of RAS, and in pancreatic cancer, where RAS mutations are near universal, RevMed's label is not restricted to one mutation.

The evidence is another. RevMed's RASolute 302 Phase 3 trial against chemotherapy hit both of its primary endpoints, overall survival and progression-free survival, and was presented in a plenary session at ASCO in 2026 with simultaneous publication in The New England Journal of Medicine. Lumakras won accelerated approval on response rate, and Amgen's own 10-K notes that after its confirmatory CodeBreaK 200 data, it received a Complete Response Letter and a new requirement for another confirmatory study.

The third reason is that the demand was waiting. RevMed ran an expanded access programme from May that, by its August report, had sent the drug to physicians for more than 2,000 patients. Those patients, plus others who had run out of options and were waiting for approval, moved to the commercial drug at launch.

Is $197.6 million a run rate?

RevMed says not. Its release states that the expanded access transition and the initial cohort of waiting patients "are finite early-launch dynamics" and that the third quarter "should not be viewed as indicative" of the longer-term trajectory. The quarter also includes initial stocking of inventory into the distribution channel; the company says it ended the quarter with less than two weeks of inventory there.

So we do not multiply five weeks by ten. More than 5,000 unique patients received commercial RASONQUE from approval to September 30, which puts revenue per patient in the launch period at under $39,520, a figure inflated by stocking and deflated by patients who started late in the quarter. The fourth quarter will be the first clean read.

What comes next?

RevMed is trying to move the drug earlier in treatment. The FDA granted Breakthrough Therapy designation for daraxonrasib with gemcitabine and nab-paclitaxel in untreated metastatic pancreatic cancer, and Phase 3 trials are running in first-line (RASolute 303) and adjuvant (RASolute 304) settings. The European Medicines Agency's committee for human medicines has recommended approval in the EU.

The company is spending to get there. It reported a third-quarter net loss of $407.5 million, research and development costs of $417.1 million, and $3.7 billion of cash and investments at September 30.

Limits

RevMed and Amgen both report US net product sales, but launch quarters are not comparable with mature years: RASONQUE's number includes channel stocking and a backlog of waiting patients, and Lumakras's 2021 figure covers only about seven months. The two drugs treat different cancers with different mutation profiles, prices and lines of therapy, so the comparison measures commercial scale, not clinical value. We use Lumakras as the yardstick because it is the first approved RAS-pathway inhibitor; Krazati (adagrasib), the second, is not in this chart because its sales sit inside Bristol Myers Squibb’s reporting after a 2024 acquisition and we did not extract a comparable series.

Sources

  1. Revolution Medicines, Third quarter 2026 financial results, Form 8-K exhibit 99.1, November 4, 2026: $197.6 million net product revenue, about five weeks of sales after the August 26 approval, more than 5,000 unique patients, channel inventory, the "finite early-launch dynamics" statement, CHMP opinion, Breakthrough Therapy designation, net loss, R&D, cash.
  2. Revolution Medicines, Second quarter 2026 financial results, Form 8-K exhibit 99.1, August 5, 2026: RASolute 302 results at ASCO and in NEJM, expanded access programme for more than 2,000 patients, RASolute 303 and 304.
  3. Amgen, Forms 10-K for 2021, 2022, 2024 and 2025: LUMAKRAS US sales of $82 million (2021), $222 million (2022), $197 million (2023), $214 million (2024) and $211 million (2025); LUMYKRAS rest-of-world sales; the CodeBreaK 200 Complete Response Letter.
  4. Amgen, Form 10-Q for the quarter ended September 30, 2026: LUMAKRAS US sales of $55 million in the third quarter of 2026.
  5. Related: KRAS G12D went from 2 trial starts to 24 in one year and FDA has approved 46 novel drugs by October 9.

Found this article helpful? Share it with your network!

Recommended Reading

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!